Corcept Therapeutics sets July 29 Q2 call as Lifyorli launch and relacorilant review take centre stage
Corcept Therapeutics will report Q2 results on July 29, with Lifyorli launch sales, Korlym growth and relacorilant’s FDA review in focus.
Pharma & Biotech
Pharma & Biotech
Corcept revives its Cushing’s bid with relacorilant, yet the hardest evidence gap remains
Read how Corcept’s relacorilant NDA resubmission could reshape Cushing’s treatment while efficacy and liver safety questions remain.
Pharma & Biotech
ROSELLA trial at ASCO 2026: Corcept’s Lifyorli subgroup data and what it means for platinum-resistant ovarian cancer practice
Corcept presents Lifyorli ROSELLA phase 3 overall survival data by prior taxane use at ASCO 2026. What the subgroup analysis means for prescribers, payers, and the EMA review. Read now.
Pharma & Biotech
Why Corcept Therapeutics now faces a bigger execution test after Lifyorli’s ROSELLA success
Corcept Therapeutics’ Lifyorli showed strong survival benefit in ovarian cancer. Read what the ROSELLA data could change for clinicians and payers.
Pharma & Biotech
Can Corcept’s Lifyorli become a real new standard in platinum-resistant ovarian cancer after FDA approval?
Corcept’s Lifyorli won FDA approval in platinum-resistant ovarian cancer. Read what the survival data could change for clinicians, rivals, and regulators.
Pharma & Biotech
Corcept’s relacorilant CRL leaves endocrinology ambitions in limbo as oncology pivot takes center stage
Find out why FDA’s complete response letter for Corcept’s relacorilant could reshape treatment of hypercortisolism, with implications for oncology approval.